TRIGEN RESOURCES INC.

Interim MD&A - Quarterly Highlights
For the three months ended July 31, 2017 and 2016

The Quarterly Highlights of Trigen Resources Inc. (the "Company" or "Trigen") provide a summary of the activities, results of operations and financial condition of the Company as at and for the three months ended July 31, 2017. The Quarterly Highlights have been prepared by management as of September 25, 2017 and should be read in conjunction with the condensed interim financial statements and related notes thereto of the Company for the three months ended July 31, 2017 and 2016, the audited financial statements and related notes thereto of the Company for the years ended April 30, 2017 and 2016, which were prepared in accordance with International Financial Reporting Standards ("IFRS"), and the annual Management Discussion and Analysis ("MD&A") of the Company prepared by management as of August 28, 2017.

The Company was incorporated on January 13, 1981 under the laws of British Columbia. The Company is listed on the NEX board of the TSX Venture Exchange (the "Exchange").

During the year ended April 30, 2011, the Company consolidated its issued and outstanding share capital on a five old for one new basis, changed its name from Hastings Resources Corp. to Trigen Resources Inc. and commenced trading under its new name and symbol, TRG, effective September 22, 2010.

On October 11, 2011, the Company's listing was transferred to the NEX board of the Exchange, and the trading symbol for the Company changed from "TRG" to "TRG.H".

On August 25, 2017, the Company completed a non-brokered private placement of 9,176,599 common shares at a price of $0.06 per common share for total gross proceeds of $550,596.

On September 13, 2017, the Company entered into a Letter of Intent ("LOI") with Bliss Co Holdings Ltd. ("BlissCo"), a private company incorporated under the laws of Canada. BlissCo is constructing an urban Access to Cannabis for Medical Purposes Regulation cultivation facility with a focus on being a high-volume packager, processor and distributor of recreational cannabis when it is legal in Canada and of medical cannabis.

Forward-looking statements

Certain statements contained in the following Quarterly Highlights constitute forward-looking statements. Such forward-looking statements include, but are not limited to statements regarding the Company's ability to identify and pursue a suitable business opportunity and its ability to raise sufficient financing to continue its operations. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors including financial, operational, environmental and political risks, general equity and market conditions. The outcome of these factors may cause the actual results and performance of the Company to be materially different from any plans or results expressed or implied by such forward-looking statements. Readers are cautioned not place undue reliance on these forward-looking statements.

Analysis of the Company's financial performance and conditions

During the three months ended July 31, 2017, the Company reported a net loss of $46,821 compared to $24,795 during the same period in fiscal 2017, an increase in loss of $22,026.

The increase in net loss during the period was primarily due to an increase in consulting expenses of

$18,750 and a decrease in interest income of $357, partially offset by a recovery of professional fee of $3,400. There were no significant variations in other operating expenses.
Increase in consulting expenses as the Company entered into a consulting agreement with a 3rd party for general business development services for a term of 12 months and a fee of $75,000 on May 8, 2017.

The recovery of professional fees of $3,400 was a credit on accrued legal fees from fiscal 2017. There is no similar recovery incurred in the current year.

There were no changes in management and administrative services fees in the comparative periods.

The Company reported a working capital of $219,837 at July 31, 2017 compared to $75,831 at April 30, 2017, representing an increase in working capital of $144,006.

Net cash and cash equivalents increased by $87,360 from $85,248 at April 30, 2017 to $172,608 at July 31, 2017 as a result of cash used in operating activities consisting of general and administrative expenses and repayments of outstanding payables.

Current assets excluding cash, as at July 31, 2017, consisted of receivables of $1,904 (April 30, 2017 - $1,935), comprised of accrued interest receivable of $nil (April 30, 2017 - $54) and sales tax credits of $1,904 (April 30, 2017 - $1,881), and prepaid expenses of $57,386 (April 30, 2017 - $833).

Current liabilities decreased by $124 from $12,185 at April 30, 2017 to $12,061 at July 31, 2017.

Subsequent to July 31, 2017, the Company closed its non-brokered private placement previously announced on April 27, 2017. 9,176,599 common shares of the Company were issued at a price of $0.06 per common share, for gross proceeds of $550,596, of which $190,700 had been received by the end of July 31, 2017. All shares issued pursuant to the private placement are subject to a four-month and one day hold period expiring December 26, 2017.

The Company has not had a history of operations or earnings and the overall success of the Company will be affected by its current or future business activities.

The Company is exposed in varying degrees to a variety of financial instrument related risks, including liquidity risk and market risks with respect to its ability to raise capital through equity markets under acceptable terms and conditions. Management monitors its activities and various factors that could impact the risks in order to manage risks and make timely decisions.

For further discussion of financial risks, please refer to Note 9 of the condensed interim financial statements for the three months ended July 31, 2017.

Transactions with Related Parties

Effective January 1, 2011, the Company entered into a management and administrative agreement with Varshney Capital Corp. (“VCC”), a company controlled by two common directors, whereby the Company agreed to pay management and administrative fees of $2,500 and $3,000 per month, respectively.

During the three months ended July 31, 2017, the Company paid $7,500 (2016 – $7,500) for management fees and $9,000 (2016 – $9,000) for administrative fees to VCC.

As at July 31, 2017, $1,312 (April 30, 2017 - $1,312) was due to a director of the Company for reimbursement of business expenses. The amount was paid subsequent to July 31, 2017.

Proposed Transaction

On September 13, 2017, the Company signed an LOI with BlissCo to complete a business combination by way of share exchange, merger, amalgamation, arrangement or similar form of transaction (the "Proposed Transaction"), whereby the security holders of BlissCo will become security holders of the combined entity (the "Resulting Issuer"). Upon completion of the Proposed Transaction the Resulting Issuer will continue to carry on the business of BlissCo as currently constituted, under the new name "BlissCo" or such other name as may be approved by the board of directors of the Resulting Issuer and the TSX Venture Exchange (the "TSXV") or, if applicable, the Canadian Securities Exchange (the "CSE"). The Proposed Transaction is an arm's length transaction and will constitute a reverse takeover of Trigen by BlissCo, pursuant to Exchange policies. In connection with the Proposed Transaction, the Resulting Issuer will apply to list its common shares on either the TSXV or the CSE (either being the "Exchange").

About BlissCo
BlissCo is constructing an urban Access to Cannabis for Medical Purposes Regulation (ACMPR) cultivation facility with a focus on being a high-volume packager, processor and distributor of recreational cannabis when it is legal in Canada, which is currently anticipated to be by July 2018, and of medical cannabis. It recently took ownership of its 12,600 sq. ft. industrial facility in Langley, British Columbia and considering the May 2017 changes Health Canada announced to the licensing process BlissCo is confident that its license will be earned shortly after completing construction.

With an ACMPR cultivation and then a sales license BlissCo will grow and sell dried cannabis and cannabis oil to approved medical patients through its online portal and service excellence call centre. BlissCo will focus on high volume sales opportunities in the legal cannabis market when individual distribution models are established by Canadian provinces and territories.

Transaction Summary
Pursuant to the LOI, the existing security holders of BlissCo will receive common shares of the Resulting Issuer in exchange for their securities of BlissCo. The final form of the transaction will be set forth in a definitive agreement to be entered into among the parties that will replace the LOI (the "Definitive Agreement").

An aggregate of 22,755,155 common shares of Trigen are currently issued and outstanding. Trigen will undertake a two and one quarter (2.25) for one (1) consolidation of its common shares in conjunction with this transaction (the "Share Consolidation"). There will be 10,113,402 Trigen shares issued and outstanding on a post-consolidated basis. It is expected that 69,963,652 post-consolidation shares of Trigen will be issued to the shareholders of BlissCo as consideration for 100% of the issued and outstanding common shares of BlissCo. Upon completion of the Proposed Transaction there will be 81,077,054 common shares issued and outstanding in the Resulting Issuer, (excluding securities issued pursuant to the Concurrent Private Placement described below), of which security holders of BlissCo will own 69,963,652 and security holders of Trigen will own 10,113,402 shares.

Completion of the Proposed Transaction is subject to a number of conditions, including, but not limited to, completion of the Share Consolidation, Exchange approval, and shareholder approval if required pursuant to Exchange, securities regulatory or corporate law requirements. In addition, completion of the Proposed Transaction is subject to certain standard closing conditions, including the completion of due diligence investigations to the satisfaction of each of Trigen and BlissCo, execution of a Definitive Agreement, and there being no material adverse change in the business of Trigen or BlissCo prior to completion of the Proposed Transaction.

Damian Kettlewell of Vancouver, British Columbia is the founder and only controlling shareholder of BlissCo and will be appointed Chief Executive Officer of the resulting issuer.

The Company has agreed to undertake a private placement offering (the "Concurrent Private Placement") of up to 11,000,000 shares at a price of $0.28 per subscription receipt for gross proceeds of up to $3,080,000. This financing will be for a minimum of $2,000,000 but may be increased up to $3,080,000. Closing of the Proposed Transaction is subject to completion of the offerings under the minimum Concurrent Private Placement.

The parties also anticipate that in conjunction with and upon closing of the Proposed Transaction, the board of directors of the Resulting Issuer shall consist of six directors, four of whom will be nominated by BlissCo. It is anticipated that BlissCo will nominate Damian Kettlewell as a director, and other directors will be disclosed in future news releases as they are identified. Trigen will have the right to elect two directors. All other current directors and officers of Trigen shall resign at or prior to the closing of the Proposed Transaction.

There is no intention of advancing any funds from Trigen to BlissCo at this time.
The Company intends to hold a special meeting of its shareholders with respect to the Proposed Transaction if required under securities laws, corporate laws or Exchange requirements.

Trading of the common shares of the Company has been halted and will remain halted in accordance with Exchange policies until all required documentation with respect to the Proposed Transaction has been received and the Exchange and securities regulatory authorities are otherwise satisfied that the halt should be lifted.

BlissCo will pay a finder's fee of 1,000,000 shares at the completion of the proposed transaction.

A press release setting out further particulars relating to the Proposed Transaction will follow in accordance with the policies of the Exchange, which will include a summary of the Definitive Agreement and transaction consideration, summary financial information of BlissCo, biographical information on the proposed directors and officers of the Resulting Issuer, and other relevant information regarding the Proposed Transaction and related financings.

Trigen may seek a waiver of Sponsorship if Sponsorship is applicable in this case.

Summary of outstanding share data as at September 25, 2017:

Authorized: Unlimited common shares without par value

Issued and outstanding: 22,755,155

Additional disclosures pertaining to the Company's management information circulars, material change reports, press releases and other information are available on the SEDAR website at www.sedar.com.

On behalf of the Board of Directors, thank you for your continued support.

"Hari Varshney"

Hari Varshney
Director